Seasonal Influenza and Pneumococcal Vaccination in the Elderly

NCT05661890 | Completed

• 1 other identifier: LokmanHekimU-SBF-HB-BA-01
• Study Type: observational
• Target: 1,166
• Locations: 1 country
• Sites: 1

Brief Summary

The elderly population and individuals with chronic diseases are at high risk for influenza and influenza-related pneumonia, and it is emphasized that taking pneumonia and influenza vaccine together is effective in reducing mortality as well as hospitalization rates and costs due to pneumonia, influenza, and congestive heart disease. This study that will be carried out will enable to determine the population-based prevalence of the relevant vaccines in the elderly and to determine the determinants of vaccination with the case group to be determined based on this. The aim of the study is two phases.

1. 1.Determination of the prevalence of seasonal influenza and pneumococcal vaccination in elderly people over the over the age of 65 living in Ankara.
2. 2.Investigation of socioeconomic characteristics and vaccine indecision and some health-related determinants of vaccination through the case group created based on the preliminary study on the prevalence of seasonal influenza and pneumococcal vaccination in the elderly over the age of 65 living in Ankara.

Conditions

Immunization; Infection; Influenza; Pneumonia; Vaccine Refusal

Keywords

Vaccine; Influenza; Pneumonia; Elderly

Outcome Measures

Primary Outcomes (1)

• Number of Influenza Vaccination uptake

  The number of self reported influenza vaccine uptake

  During 2022

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The population is individuals over the age of 65 living in the central district of Ankara. The sample size required for the study and its distribution by neighborhoods were calculated according to the WHO LKT modüle. The minimum required sample size was calculated as 972, by accepting the preliminary decision that 75 lots would be used in the study, and p=35%, 95% confidence interval, and deviation value of ±3 in the study. However, the minimum sample size for the number of elderly per LOT was accepted as 15 and the number was increased by 20% considering possible data losses and the sample size was accepted as 1166. The region of each lot was determined on the map, and sample selection was made using random methods in the study.

You may qualify if:

• Over the age of 65.

You may not qualify if:

• Cancer diagnosis
• Having a disease that will require immunosuppressive treatment
• Transplantation cases
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Inflammatory bowel disease

Sponsors & Collaborators

• Lokman Hekim University: lead

Study Sites (1)

Lokman Hekim University

Ankara, Çankaya, 06510, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Infections; Influenza, Human; Pneumonia; Vaccination Refusal

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Lung Diseases; Treatment Refusal; Treatment Adherence and Compliance; Health Behavior; Behavior

Study Officials

• Belgin Akın

  Lokman Hekim University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 14, 2022
• First Posted: December 22, 2022
• Study Start: November 15, 2022
• Primary Completion: January 30, 2023
• Study Completion: February 15, 2023
• Last Updated: February 24, 2023

Record last verified: 2023-02

Locations

TU (1)